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ABSTRACT
The aim of this study was to clarify the synergistic effects of dual inhibition of 
the PI3K/mTOR and MAPK pathways in ovarian mucinous carcinoma (OMC) cells, 
using fluorescence resonance energy transfer (FRET) imaging. We exposed 6 OMC 
cell lines to a PI3K/mTOR inhibitor (voxtalisib, SAR245409) and/or a MEK inhibitor 
(pimasertib), and evaluated synergistic effects using the Chou–Talalay method. Then, 
S6K (PI3K pathway) and ERK (MAPK pathway) kinase activities, and their individual 
proliferative or cytotoxic effects were calculated by time-lapse FRET imaging. In 
combination with SAR245409, pimasertib (30 nM) synergistically inhibited cell growth 
(combination indexes: 0.03–0.5) and induced apoptosis in all 6 OMC cell lines. FRET-
imaging results demonstrated that ERK inhibition induced both anti-proliferation and 
apoptosis in a dose-dependent manner in both MCAS and OAW42 cells. However, 
S6K inhibition suppressed proliferation in a threshold manner in both cell lines, 
although apoptosis was only induced in OAW42 cells. These results demonstrated 
that combined PI3K/mTOR and MEK inhibition exhibited synergistic antitumor effects 
in OMC cells and that FRET imaging is useful for analyzing kinase activities in live cells 
and elucidating their cytostatic and cytotoxic effects.
INTRODUCTION
Ovarian cancer is a leading cause of death among 
patients with gynecologic malignancies [1, 2]. Ovarian 
mucinous carcinomas (OMC) accounts for ~10% of 
epithelial ovarian carcinomas [3]. Although a high 
proportion of OMCs are confined to the ovary and cured 
mainly by surgical excision, patients with advanced 
OMC have a poorer prognosis due to low sensitivity to 
platinum-based chemotherapy [4–7]. The mechanism of 
chemoresistance remains unknown, and chemotherapy-
based clinical trials are difficult to perform due to limited 
participants. Therefore, novel treatment options for 
advanced or recurrent OMC should be established based 
on the tumor biology. However, limited studies have 
related to targeted molecular therapies against OMC [7, 8]. 
The mitogen-activated protein kinase (MAPK) pathway 
might represent one possible target in OMC, because 
mutations in the KRAS GTPase gene are frequent in OMC 
(50–60%) [9], and exome-level sequencing studies in 
OMC revealed various genetic alterations in the MAPK 
pathway [10]. Although phosphatidylinositol 3-kinase 
(PI3K)-activating mutations, such as PIK3CA and PTEN, 
are rare (<10%) in OMC [11], KRAS mutations can 
also activate the PI3K/mammalian target of rapamycin 
(mTOR) pathway [12]. Accordingly, a PI3K/mTOR 
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inhibitor, NVP-BEZ235, suppressed cell proliferation in 
OMC cell lines [8]. In addition, co-targeting the PI3K/
mTOR and MAPK pathways synergistically inhibited 
the growth of various ovarian cancer cell lines [13]. 
However, the antitumor effects of these drugs vary 
significantly among cancer types [14], which might relate 
to the complexity of the signaling networks [15, 16]. 
We recently reported that combination treatment with a 
PI3K/mTOR inhibitor, SAR245409 (voxtalisib), and a 
MEK inhibitor, pimasertib, showed synergistic antitumor 
effects in 6 out of 12 endometrial cancer cell lines and that 
mutational statuses of KRAS, PIK3CA, and PTEN were 
not involved [17]. Pimasertib, alone or in combination 
with SAR245409, is currently being investigated in Phase 
I–II trials. Collectively, these findings suggest that co-
targeting the PI3K/mTOR and MAPK pathways might be 
a therapeutic option for certain OMC cells and that the 
synergy of dual inhibition might differ among cell lines, 
even within the same OMC histological types.
Quantitative monitoring of intracellular signaling in 
living cells is enabled by recent advances in biosensors, 
based on fluorescence resonance energy transfer (FRET). 
To date, FRET biosensors have enabled visualization of 
a wide range of cellular events such as protein kinase 
activities, protein-protein interactions, and second-
messenger activities [18, 19]. Using FRET biosensors for 
ERK and S6K, we demonstrated differences in sensitivity 
to MEK and PI3K inhibitors in KRAS- and BRAF-mutant 
lung or colorectal cancer cell lines [20, 21]. However, 
FRET imaging has not yet been applied to ovarian cancers, 
including OMC.
Here, we evaluated the synergistic antitumor effects 
of combination treatment with a PI3K/mTOR inhibitor 
(SAR245409) and a MEK inhibitor, pimasertib, in OMC 
cells. We also quantified the activity of S6K (in the PI3K/
mTOR pathway) and ERK (in the MAPK pathway) 
in OMC cells under various treatment concentrations 
and durations via FRET imaging. Finally, we derived 
a mathematical model to directly associate the kinase 
activities of S6K or ERK with the anti-tumor effects 
(cytostatic and/or cytotoxic) of these compounds in OMC 
cells.
RESULTS
Antiproliferative effect of SAR245409 and 
pimasertib in OMC cell lines
We evaluated the anti-tumor effects of each single 
agent, SAR245409 and pimasertib, in 6 OMC cell lines 
by performing methyl thiazolyl tetrazolium (MTT) 
assays. The mutational statuses of PIK3CA, PTEN, and 
mTOR (PI3K-pathway genes) and KRAS and BRAF 
(MAPK-pathway genes) are shown in Figure 1A. MCAS 
cells harbor mutations in both KRAS and PIK3CA, and 
JHOM-2B cells harbor mutations in both BRAF and 
mTOR. OAW42 and JHOM-1 cells harbor a PIK3CA 
and PTEN mutation, respectively. The half-maximal 
inhibitory concentration (IC50) values of SAR245409 and 
pimasertib varied from 0.6 to 6 μM and 1.0 to >20 μM, 
respectively (Figure 1A). Although the IC50 of pimasertib 
in OAW42 was higher than those in the other 5 cell lines, 
no significant difference in pimasertib sensitivity was 
observed among the other 5 lines.
The effects of SAR245409 and pimasertib on each 
target pathway were evaluated by immunoblotting (Figure 
1B), and the phosphorylation levels of the target proteins 
were quantified using Image J software (Figure 1C). In 
MCAS and OAW42 OMC cells, 1 μM SAR245409 or 
higher was required to suppress the phosphorylation of 
AKT (Ser473, p-AKT) and S6K (Thr389, p-S6K), and 
a 30–300 nM or higher dose of pimasertib suppressed 
ERK phosphorylation (p-ERK). Overall, the IC50 values 
of the PI3K/mTOR- and MEK-pathway inhibitors were 
much higher than the minimum doses required to suppress 
phosphorylation of their target proteins, suggesting that 
inhibition of either pathway alone might be insufficient to 
inhibit cell proliferation.
Synergistic effects of the combination of 
SAR245409 and pimasertib
Next, we examined whether the antitumor effects 
of SAR245409 and pimasertib were synergistic in 
combination. Based on immunoblotting data (Figure 
1B and 1C), we performed the MTT assays under 
fixed pimasertib concentrations of 10, 30, or 100 nM, 
combined with various SAR245409 concentrations 
(Figure 2A, Supplementary Table 1). The effect of 30-
nM pimasertib was comparable with that at 100 nM 
in all 6 OMC cell lines. However, 10-nM pimasertib 
combined with SAR245409 did not show an additive 
effect in any cell lines except for JHOM-1 (Figure 2A, 
Supplementary Figure 1A). Therefore, we calculated the 
combination indexes (CIs) using the Talalay–Chou method 
by adding 30-nM pimasertib with various SAR245409 
concentrations to OMC cells. The resultant CIs ranged 
from 0.03 to 0.50 in these 6 cell lines (Figure 2B), 
suggesting that the synergistic effect was broadly induced 
in OMC cells independently of the KRAS and PIK3CA 
mutational statuses.
We also performed MTT assays under fixed 
SAR245409 concentrations (300 nM or 1 μM), in 
combination with various pimasertib concentrations. 
The anti-proliferative effect of SAR245409 at 300 nM 
increased with a low dose of pimasertib (100 nM), and 
this effect was not further enhanced when combined with 
a higher dose of pimasertib (>300 nM; blue vs. green line; 
Figure 2C, Supplementary Table 2). In agreement with 
the data shown in Figure 2A, cell proliferation was more 
Oncotarget29579www.impactjournals.com/oncotarget
robustly inhibited by combination treatment with 1-μM 
SAR245409 compared with that at 300 nM (green vs. red 
line; Figure 2C, Supplementary Figure 1B).
We then examined whether the combination of 1 
μM SAR245409 and 30 nM pimasertib could effectively 
inhibit the phosphorylation of target proteins in the PI3K 
and MAPK pathways. AKT and S6K phosphorylation was 
suppressed by SAR245409 at 1 μM, but not by pimasertib. 
In addition, ERK phosphorylation decreased by pimasertib 
at 30 nM in both MCAS and OAW42 cells (Figure 2D). 
p-ERK levels in OAW42 cells were more robustly 
suppressed by the combination of SAR245409 at 1 μM 
and pimasertib at 30 nM, compared with pimasertib at 30 
nM alone (Figure 2D).
Apoptosis induction by combination treatment 
with SAR245409 and pimasertib
By flow cytometry, 1-μM SAR245409 with 30-nM 
pimasertib markedly decreased the S phase population 
(from 10.4–23.6% to 2.2–6.0%) in all three tested cell 
lines (MCAS, OAW42, and JHOM-2B), and increased the 
sub-G1 population in MCAS and JHOM-2B cells (Figure 
3A). Furthermore, Annexin V-assay results revealed that 
this combination markedly increased the ratio of apoptotic 
cells in all three cell lines (Figure 3B).
Figure 1: Inhibition of cell proliferation by SAR245409 and pimasertib. A. Calculation of the IC50 values of SAR245409 and 
pimasertib according to MTT assay data. The results are shown as the mean ± SE of 3 independent experiments. The IC50 of pimasertib for 
OAW42 cells was >20 μM. The table shows the mutation statuses of each cell line. B. Western blot analysis of MCAS and OAW42 cell 
lysates, following treatment with SAR245409 (0–3,000 nM) or pimasertib (0–1,000 nM) for 3 h. p-AKT, p-S6K, and p-ERK levels were 
evaluated to assess suppression of the PI3K, mTOR, and MAPK pathways, respectively. C. Quantified ratios of p-AKT and p-S6 to total 
AKT and S6 protein levels in response to SAR245409, as well as p-ERK levels in response to pimasertib. Levels were quantified using 
Image J software. The results are shown as the mean ± SE of 3 independent experiments.
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Figure 2: Enhanced antitumor effects of combination treatment with SAR245409 and pimasertib. A. MTT assays 
following combination SAR245409 and pimasertib treatment. The pimasertib concentration was fixed at 100, 30, or 10 nM, and the 
data were compared with those following treatment with SAR245409 alone. The results are shown as the mean ± SE of 3 independent 
experiments. B. CIs were calculated using the Chou–Talalay method. Each cell line was treated with 30-nM pimasertib and SAR245409 
(30–10,000 nM). A CI <1.0 indicated a synergistic effect. C. MTT assays following combination therapy. The SAR245409 concentration 
was fixed at 300 or 1 μM, and the data were compared with those obtained after treatment with pimasertib alone. The results are shown 
as the mean ± SE of 3 independent experiments. D. Phosphorylation of AKT, S6K, and ERK were evaluated by western blotting after 
treatment with 1-μM SAR245409, 30-nM pimasertib, or a combination thereof.
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Knockdown of either MEK1/2 or ERK1/2 
enhances cell sensitivity to SAR245409
To confirm the effect of inhibiting the MAPK 
pathway with combination treatment, we silenced 
MEK 1/2 or ERK1/2 in OAW42 cells before treatment 
with various SAR245409 concentrations. MEK 1/2 and 
ERK1/2 expression were suppressed by >80% using 
two small-interfering RNAs (siRNAs) against each gene 
(Figure 4A). SAR245409 and either MEK 1/2 or ERK1/2 
gene silencing significantly suppressed cell proliferation, 
compared to SAR245409 treatment alone (relative to 
SAR245409 and the negative control siRNA) in OAW42 
cells (Figure 4B, Supplementary Table 3).
S6K- and ERK-activity quantification by FRET 
imaging
We employed FRET biosensors for ERK and S6K, 
namely EKAREV-NLS and Eevee-S6K-NES, respectively 
(Figure 5A). These biosensors are phosphorylated by 
endogenous ERK or S6K, leading to intramolecular 
binding between sensor and ligand domains. The 
associated conformational change brings YFP in close 
proximity to CFP, allowing FRET [22]. We generated 
cell lines stably expressing either the ERK or S6K FRET 
biosensor in MCAS and OAW42 cells using a transposon 
system. MCAS cells expressing EKAREV-NLS (Figure 
5B) or Eevee-S6K-NES (Figure 5C) were treated with 
pimasertib and SAR245409 for 3 h. Pimasertib dose-
dependently suppressed ERK activity, which correlated 
with FRET/CFP ratios (Figure 5B), in agreement with 
the immunoblotting data (Figure 1B, 1C, and 2D), 
showing that p-ERK activity was suppressed by 30–100 
nM or higher pimasertib doses. S6K activity in MCAS 
cells exhibited a bell-shaped response to SAR245409; 
i.e., a low dose of SAR245409 (~100 nM) preferentially 
activated S6K activity, and a high dose suppressed S6K 
activity (Figure 5C). These data were consistent with 
the biochemical data (Figure 1C, middle and lower 
left), validating the use of these FRET biosensors for 
quantitative analysis.
Employing FRET imaging in living cells, we 
quantified ERK and S6K activity in MCAS (Figure 5D, 
5E) and OAW42 (Supplementary Figure 2A, 2B) cells, 
which were seeded on 96-well glass-bottom plates and 
treated with 64 different combinations of pimasertib 
and SAR245409 concentrations for 0 min, 30 min, 3 
Figure 3: Apoptosis induced by combination SAR245409 and pimasertib treatment. A. Flow cytometric analysis of the cell 
cycle in MCAS (left), OAW42 (middle), and JHOM-2B (right) cells treated with 1-μM SAR245409, 30-nM pimasertib, or a combination 
thereof. B. Annexin V-assay results in the 3 cell lines examined in A. The results are shown as the mean ± SE of 3 independent experiments.
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h, 1 day, or 2 days. S6K was activated at a low dose of 
SAR245409 (0.1 nM) from 30 min to 1 day in MCAS 
cells (Figure 5D). The observed S6K inhibition at a high 
pimasertib dose (> 0.32 μM) on day 1 (Figure 5D) agreed 
with our previous finding of mTOR upregulation via ERK-
dependent transcription in KRAS-mutant cancer cells 
[21]. Here, ERK activity was clearly inhibited 30 min 
after treatment with a low pimasertib dose (0.032–0.32 
μM), but was reactivated at 3 h and later after treatment 
(Figure 5E). This response might be due to negative 
feedback from ERK to Sos, Raf, and/or MEK [23–26]. 
A high SAR245409 dose (10 μM) also inhibited ERK 
activity at each time point (Figure 5E). This suppression 
was potentially caused by crosstalk between the MAPK 
and PI3K/mTOR pathways; either pathway's activity can 
be suppressed especially when using high-concentration 
chemical inhibitors [27]. Both S6K and ERK activities in 
cultured cells were slightly reduced at 48 h even in the 
absence of SAR245409 and pimasertib (Figure 5D and 
5E, 2 days), which might have been caused by contact 
inhibition.
Roles of S6K and ERK activity in cell 
proliferation and cell death
To link ERK and S6K activity to cancer cell 
phenotypes (proliferation and cell death), we measured 
the numbers of live and dead cells in MTT and lactate 
dehydrogenase (LDH) assays 2 days after inhibitor 
treatments under the conditions described for Figure 
5D and 5E. The numbers of live and dead cells were 
normalized to values from reference wells. SAR245409 
or pimasertib treatment alone showed cytostatic and 
cytotoxic effects, and the combination showed synergistic 
effects in MCAS cells (Figure 6A). In OAW42 cells, 
SAR245409 treatment induced more potent cytostatic 
and cytotoxic effects than pimasertib (Supplementary 
Figure 3).
Finally, we combined the cell-proliferation and 
cell-death data (Figure 6A and Supplementary Figure 3) 
from the FRET-imaging, using a mathematical model 
to evaluate the contributions of S6K and ERK to cell 
proliferation and cell death in MCAS and OAW42 
Figure 4: Enhanced sensitivity to SAR245409 by MEK1/2 or ERK1/2 knockdown. A. Suppression of MEK1/2 or ERK1/2 
expression by siRNAs was confirmed by immunoblotting. siRNAs targeting MAP2K1 and MAP2K2, or MAPK3 and MAPK1 (20 nM 
each) were transfected into OAW42 cells in various combinations. (i) siMEK1/2-1, (ii) siMEK1/2-2, (iii) siERK1/2-1 and (iv) siERK1/2-2 
correspond to mixtures of (i) HSS108559 and HSS183388, (ii) HSS108560 and HSS183389, (iii) HSS108538 and HSS183535, and (iv) 
HSS108539 and HSS183536, respectively. Non-silencing siRNA (siCT) was used as a control. B. MTT assays were performed in OAW42 
cells under exposure to SAR245409 (30–100,000 nM) following lipofection with siRNAs to either MEK1/2 or ERK1/2. The results are 
shown as the mean ± SE of 3 independent experiments.
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cells. We derived an “AND gate” model, in which the 
multiplication of ERK and S6K activities dictated the 
proliferation and cell death (Figure 6B). After parameter 
fitting, we obtained Hill functions for the ERK and S6K 
activities toward proliferation and cell death. ERK and 
S6K activity linearly augmented MCAS and OAW42 cell 
proliferation (Figure 6C, 6D). Comparatively, S6K activity 
promoted cell proliferation in a threshold manner. Notably, 
the threshold value of S6K in OAW42 cells (~0.3) was 
higher than that in MCAS cells (~0.15), indicating that 
OAW42 cells were more sensitive to the PI3K/mTOR 
inhibitor (Figure 6C, 6D). Figure 6E and 6F show the 
cell-death levels at the indicated S6K and ERK activities. 
In MCAS cells, lower ERK activity induced cell death 
with relatively high cooperativity, whereas S6K activity 
did not promote cell death (Figure 6E). Therefore, ERK 
activity should be inhibited to induce cytotoxicity in 
MCAS cells. However, inhibition of both ERK and S6K 
activities was required to induce cell death in OAW42 
cells (Figure 6F). Collectively, these results demonstrated 
quantitative differences of sensitivities to MEK or PI3K/
mTOR inhibitors between MCAS and OAW42 cells.
DISCUSSION
Here, we found that (i) combination PI3K/mTOR- 
and MEK inhibitor-treatment synergistically suppressed 
cell growth in OMC cell lines; (ii) the synergistic effect 
was dependent on both cytostatic and cytotoxic effects; 
and (iii) multi-well FRET imaging and mathematical 
modeling revealed that S6K and ERK activities 
contributed to the cytostatic or cytotoxic effects.
Combination therapy with SAR245409 and 
pimasertib induced synergistic antitumor effects in 
all 6 OMC cell lines tested. Considering the low 
chemosensitivity of OMC, combination therapy might be 
Figure 5: S6K and ERK activity observed by time-lapse FRET imaging. A. FRET biosensor scheme. A biosensor is 
phosphorylated by endogenous ERK or S6K, leading to an increase in FRET. B, C. MCAS cells stably expressing ERK (B) or S6K (C) 
FRET biosensors were treated with the indicated concentration of pimasertib (B) or SAR245409 (C) for 3 h. 
(Continued )
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Figure 5 (Continued ): D. S6K activity of MCAS cells treated with SAR245409 and pimasertib at various concentrations was quantified 
before, and at 30 min, 3 h, 1 day, and 2 days post-treatment. The concentrations of each drug are indicated. The values in each panel 
demonstrate the average of FRET/CFP ratio (N > 10 cells), indicating S6K activity. Red and blue colors represent higher and lower S6K 
activity, respectively. The results shown are representative of two independent experiments. E. The ERK activity of MCAS cells treated 
with SAR245409 and pimasertib as in panel D. The values in each panel demonstrate the average of the FRET/CFP ratio (N > 10 cells), 
indicating ERK activity. Red and blue colors represent higher and lower ERK activity, respectively. The results shown are representative 
of two independent experiments.
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Figure 6: S6K and ERK roles in cell proliferation and cell death are cell-line dependent. A. Cytostatic and cytotoxic 
effects of SAR245409 and/or pimasertib treatment in MCAS cells were measured by MTT (upper left) and LDH (upper middle) assays. 
SAR245409 and/or pimasertib were used as described in Figure 5. Cell numbers were calculated based on the sum of live and dead cells 
(upper right). Values were normalized to the number of control cells following DMSO treatment. Red and blue colors represent higher 
and lower values, respectively. The results represent the averaged values of 3 independent experiments. The synergy index was calculated 
using Bliss independence. B. Cell-proliferation data (Figure 6A) in MCAS cells were fitted with ERK- and S6K-activity data, based on the 
“AND gate” model. 
(Continued )
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promising for advanced or recurrent OMC patients. The 
IC50 values for pimasertib alone were much higher (>1 
μM) than the doses required to suppress p-ERK production 
(30–300 nM). Therefore, the PI3K/mTOR pathway was 
considered essential for cell proliferation and/or cell 
survival. Synergistic effects mediated by inhibiting both 
the PI3K and the MAPK pathways have been reported 
for several types of cancers [28–30], and activation of 
the RAS/MAPK pathway may be associated with the 
synergistic effects of the PI3K/mTOR- and MEK-pathway 
inhibitors [31, 32]. Our data support the importance of 
inhibiting the PI3K/mTOR and MAPK pathways in OMC 
cells. Although the mutation rates of the PI3K-pathway 
genes were generally low in OMC clinical samples [11], 
the PI3K/mTOR pathway mutations (PIK3CA, PTEN, or 
mTOR) were identified in 3 of 6 OMC cells. Here, the IC50 
values were ≤2.5 μM for pimasertib in cells with KRAS 
or BRAF mutations, and were ≤2.0 μM for SAR245309 
in cells with PIK3CA, PTEN, or mTOR mutations. 
Therefore, the sensitivity of these compounds may reflect 
the mutational status. As ERK1/2 knockdown increased 
SAR245409 sensitivity comparably to that observed 
following MEK1/2 knockdown, ERK inhibition would 
be essential for synergistically co-targeting the PI3K and 
MAPK pathways. It should be further clarified how the 
activity of each component of the PI3K/mTOR and MAPK 
pathways promotes sensitivity to single or combination 
treatment with PI3K/mTOR and MEK inhibitors.
Combination treatment markedly induced apoptosis 
in OMC cells. As OMC cells are generally resistant to 
conventional chemotherapy, synergistic cytotoxicity 
of combination treatment (as with SAR245409 and 
pimasertib) might be a promising approach for this cancer. 
The combination treatment also increased the population 
of G2/M phase cells. Therefore, this combination induced 
both cytotoxic and cytostatic effects. As both the MAPK 
and PI3K pathways are broadly activated in ovarian 
endometrioid, clear cell, and low-grade serous carcinomas, 
this combination might have synergistic antitumor effects 
on other histological types of ovarian cancer [9, 33].
Using FRET-imaging and mathematical modeling, 
we quantitated the differing cytostatic and cytotoxic 
effects following combination therapy in OMC cell lines. 
Time-lapse FRET imaging was previously employed 
in several cancer types [34–36]. However, this is the 
first report of the application of FRET biosensors to 
Figure 6 (Continued ): C, D. Contributions of ERK (red lines) and S6K (blue lines) activity to cell proliferation in MCAC (C) and 
OAW42 (D) cells are plotted based on mathematical models and parameter estimations. E, F. Contributions of ERK (red lines) and S6K 
(blue lines) activity to cell death in MCAC (E) and OAW42 (F) cells are plotted, based on mathematical models and parameter estimations.
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analyze molecularly targeted drugs in ovarian cancer 
cell lines. FRET-imaging systems and mathematical 
modeling enabled us to investigate (i) how treatment 
with molecularly targeted drugs alone or in combination 
affected target kinase activities with various durations and 
dosages in live cells in a single assay, (ii) how the targeted 
kinases affected each other through feedback and/or 
feedforward regulation, and (iii) how each kinase activity 
contributed to cell proliferation and cell death. In two cell 
lines, the ERK inhibition blocked cellular proliferation 
and induced cell death, both of which were almost linearly 
associated with ERK activity. In contrast, S6K activity 
inhibited cell proliferation in a threshold manner. ERK 
inhibition slowly reduced S6K activity, which may reflect 
the synergistic effects of combination treatment with MEK 
and PI3K/mTOR inhibitors. Although the inhibition of 
S6K activity was indispensable for inducing cell death in 
OAW42 cells, it did not show any dose-dependent effect 
on MCAS cell proliferation. These results are consistent 
with the mutational status of the KRAS or PIK3CA genes; 
namely, MCAS cells harbor KRAS and PIK3CA mutations 
and exhibit greater sensitivity to MEK inhibitors than to 
PI3K/mTOR inhibitors. In contrast, OAW42 cells harbor 
only PIK3CA mutations, suggesting a higher sensitivity 
to PI3K/mTOR inhibitors than to MEK inhibitors. Future 
studies and careful consideration will be needed to 
evaluate the relationship between mutation statuses and 
the effects of molecularly targeted drugs, as FRET reflects 
both exogenous and endogenous kinase activities.
Our study has several limitations. First, the 
synergistic mechanisms between SAR245409 and 
pimasertib, as well as the cytotoxic mechanisms elicited 
by inhibiting the associated pathways, were not fully 
elucidated. Second, time-lapse FRET imaging was 
analyzed in only two cell lines, and further study is 
warranted to clarify similarities and differences among 
various OMC cell lines. Third, in vivo preclinical studies 
and/or clinical trials are required to evaluate the synergistic 
effects and feasibility of this combination therapy in OMC. 
However, good efficacy and feasibility of SAR245409 and 
pimasertib have been reported in clinical trials and mouse 
xenograft models [37, 38]. The maximum-tolerated doses 
for the combination are within the range of the active 
doses of each drug as monotherapies in clinical trials [37], 
and the combination showed robust antitumor activity 
without significant additive effects in an ovarian cancer-
xenograft mouse model [38].
In summary, our results demonstrated that 
combination therapy with SAR245409 and pimasertib 
synergistically induced cytotoxic and cytostatic responses 
in OMC cells. We also found that activation of both the 
PI3K and MAPK pathways is essential for these effects, 
and that their relative contributions might vary among cell 
types. We also showed that FRET-imaging systems can 
be useful for analyzing the mechanisms of action of each 
drug in combination therapies against cancer cells.
MATERIALS AND METHODS
Cell lines and inhibitors
MCAS and OAW42 cells were purchased 
directly from the American Type Culture Collection 
(Manassas, VA, USA). JHOM-1, JHOM-2B, OMC3, and 
RMUG-S cells were purchased directly from the Riken 
BioResource Center (Ibaragi, Japan). Both cell banks 
routinely characterize their cell lines. Assays completed 
with these cell lines were completed in our laboratory 
within 6 months after resuscitation. MCAS and OAW42 
were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) with 10% fetal bovine serum (FBS), and JHOM-
2B cells were maintained in DMEM: Nutrient mixture 
F12 (DMEM/F12) with 10% FBS. The remaining cell 
lines were maintained in F12 with 10% FBS. SAR245409 
and pimasertib were provided by Sanofi (Paris, France) 
and Merck Serono (Darmstadt, Germany), respectively. 
SAR245409 is a highly selective and potent ATP-
competitive inhibitor of pan-class I PI3Ks and mTORC1/
mTORC2 [17, 39]. Pimasertib is a highly potent ATP-
noncompetitive second-generation inhibitor of MEK1 
and MEK2. Pharmacological information regarding 
SAR245409 and pimasertib including molecular-structure 
and preliminary toxicity data have been published [39, 
40]. Both agents are orally bioavailable small-molecule 
inhibitors and have been tested in phase I/II clinical 
trials for malignant tumors (ClinicalTrials.gov Identifier: 
NCT01936363). The mutational statuses of KRAS, 
BRAF, PIK3CA, PTEN, and mTOR were confirmed by 
the COSMIC (http://cancer.sanger.ac.uk/cell_lines) and 
Cancer Cell Line Encyclopedia databases (http://www.
broadinstitute.org/ccle/home), and polymerase chain 
reaction amplification and direct sequencing [13, 41, 42].
Proliferation and cytotoxicity assays
Cell proliferation was evaluated in MTT assays 
using the Cell Counting Kit-8 (Dojindo, Tokyo, Japan) or 
Cell Count Reagents SF (Nacalai Tesque, Kyoto, Japan), 
both of which employ 2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulfophenyl) -2H-tetrazolium, 
monosodium salt [17, 41]. Cells were seeded in 96-
well plates at 2 × 103–1 × 104 cells/well and exposed 
to each drug for 72 h. Cell proliferation was quantified 
by monitoring changes in the absorbance at 450 nm. 
Cytotoxicity was measured by LDH release into the 
culture medium. Briefly, cells were prepared as described 
for the cell-proliferation assay. The cultured medium 
(50 μl) was transferred to 96-well plates, and LDH 
was measured using the CytoTox-ONE Homogeneous 
Membrane Integrity Assay (Promega, Madison, WI, 
USA), according to the manufacturer’s protocol. The IC50 
values were determined from the dose-response curves. 
Each experiment was repeated at least three times.
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Immunoblotting
Cells (5 × 105) in 6-well plates were exposed to 
SAR245409 and/or pimasertib for the indicated times 
at the indicated concentrations and lysed as described 
previously [43]. Primary antibodies against AKT, 
p-AKT (Ser473), S6K, phosphorylated S6K (p-S6K), 
ERK, p-ERK (ERK1/2-Thr202/Tyr204) (Cell Signaling 
Technology, Beverly, MA, USA), and beta-actin 
(Sigma-Aldrich, St. Louis, MO, USA) were used for 
immunoblotting [17, 23]. Signals were detected using an 
immunoblotting system (BioRad Laboratories, Hercules, 
CA, USA) with ECL Select Detection agents (GE 
Healthcare, Piscataway, NJ, USA). Immunoblotting results 
were quantified using Image J software [44].
Cell cycle analysis
Cells (5 × 105) were seeded in 60-mm dishes and 
treated with SAR245409 and/or pimasertib for 72 h. 
Both floating and adherent cells were collected after 
trypsinization, and cell-cycle distribution was analyzed by 
flow cytometry (BD FACSCalibur HG, Franklin Lakes, 
NJ, USA) and CELLQuest pro ver. 3.1 software (Beckman 
Coulter Epics XL, Brea, CA, USA) [41]. All experiments 
were repeated three times.
siRNA transfections
siRNAs were used to inhibit expression of MAP2K1, 
MAP2K2, MAPK3, and MAPK1, encoding MEK1, MEK2, 
ERK1, and ERK2 proteins, respectively. siRNAs specific 
to MAP2K1 (HSS108559, 108560, 108561), MAP2K2 
(HSS183388, 183389, 183390), MAPK3 (HSS108538, 
108539), and MAPK1 (HSS183535, 183536) were 
purchased from Invitrogen (Carlsbad, CA, USA). Non-
silencing siRNA (siCT) (Stealth RNAi siRNA Negative 
Control Kit; Invitrogen) was used as a control. OAW42 
cells were seeded 24 h before transfection to reach ~30% 
confluence in 100-mm plates and transfected with 20-
nM siRNA duplexes using Lipofectamine RNAiMAX 
(Invitrogen).
Statistical analysis
The means ± SEMs from 3 independent experiments 
were determined. The significance of differences was 
analyzed by Student’s t-test, and p < 0.05 was considered 
statistically significant. For combination experiments 
with SAR245309 and pimasertib, or rapamycin and 
pimasertib, CIs were calculated according to the Chou–
Talalay method, using the IC50 values under monotherapy 
and combination therapy [45]. Synergism, additive effects, 
and antagonism were defined as CI < 1, CI = 1, and CI > 
1, respectively.
FRET biosensors and the establishment of 
biosensor-expressing mucinous ovarian cancer 
cell lines
FRET biosensors for ERK and S6K were developed 
previously [46]. Stable cell lines expressing ERK and 
S6K FRET biosensors using a transposon system were 
established, as described previously [47]. MCAS and 
OAW42 cells were transfected with pT2Apuro-HistoneH1-
mCherry and pCAGGS-T2TP as nuclear markers. After 
selection with puromycin (Sigma) at 1.0 μg/ml for 7 days, 
cells were further transfected with pCMV-mPBase and 
either pPBbsr-EKAREV-nls or pPBbsr-Eevee-S6K-nes, 
and selected with blasticidin S at a dose of 10 μg/ml for 
7 days (InvivoGen, San Diego, CA, USA) to generate 
cells expressing EKAREV-nls/Histone H1-mCherry 
or Eevee-S6K/Histone H1-mCherry. Plasmids were 
transfected using FuGENE HD (Promega) according to 
the manufacturer’s instructions.
Multi-well FRET imaging
FRET images were obtained and processed as 
described previously [21, 48]. Briefly, 3,000 cells/well 
expressing EKAREV-nls/Histone H1-mCherry and Eevee-
S6K/Histone H1-mCherry were mixed and plated in 96-
well, glass-bottom plates (Asahi Techno Glass; Tokyo, 
Japan). After attachment, the media was exchanged for 
200 μl of imaging medium comprised of Medium 199 
(Sigma) with 20 mM HEPES, 10% FBS, and penicillin/
streptomycin. Cells were cultured in CO2 incubators, and 
images were captured at the specified time points using an 
inverted fluorescence microscope (IX83; Olympus, Tokyo, 
Japan) equipped with a cooled CCD camera (DOC CAM 
HR; Molecular Devices, Sunnyvale, CA), an illumination 
system (CoolLED precisExcite; Molecular Devices), an 
IX2-ZDC2 laser-based autofocusing system (Olympus), 
a MAC5000 filter wheel controller (Ludl Electronic 
Products, Hawthorne, NY, USA), an XY stage (SIGMA 
KOKI, Tokyo, Japan), and an incubation chamber (Tokai 
Hit, Shizuoka, Japan). The following filters were used for 
FRET, CFP, and mCherry imaging: 430/24 (Olympus) for 
FRET and CFP excitation, 572/35 (Olympus) for mCherry 
excitation, XF2034 dichroic mirror (Omega, Brattleboro, 
VT, USA) for FRET and CFP, 86006bs dichroic mirror 
(Chroma, Brattleboro, VT, USA) for mCherry, FF483/32 
(Semrock, Rochester, NY, USA) for CFP emission, 
FF542/27 (Semrock) for FRET emission, and FF01-641/75 
(Semrock) for mCherry emission. Cells were imaged with 
an UPlanSApo ×20 dry objective lens (Olympus). The 
same four positions were acquired in each well during the 
time-course experiments. The microscope was controlled 
by MetaMorph software (Molecular Devices).
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Mathematical modeling
ERK- and S6K-activity data from MCAS and 
OAW42 cells were utilized as inputs to reproduce cell 
proliferation, and cell death was utilized as the output. 
The following equations were derived as an “AND gate” 
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where Proliferationsim and Deathsim indicate the simulated 
number of total cells and dead cells, respectively (0 < 
Proliferationsim < 1, 0 < Deathsim < 1). We also prepared 
two additional wells having the same cell numbers, 
without inhibitors, and measured live cells in 1 well in 
an MTT assay, while we induced cell death with an SDS-
containing solution and measured dead cells in LDH 
assay in the other well. These data demonstrated how 
many cells were produced in individual wells, indicating 
effects on cell proliferation, which is inversely related 
to cytostatic effects. ERK and S6K represent normalized 
ERK and S6K activities as measured by FRET imaging 
3 h post-inhibitor treatment, respectively (0 < ERK < 1, 0 
< S6K < 1). The fitted parameters are as follows: nHERK_P 
and nHS6K_P are Hill coefficients for ERK and S6K in 
Proliferationsim, respectively. nHERK_D and nHS6K_D are Hill 
coefficients for ERK and S6K in Deadhsim, respectively. 
EC50ERK and EC50S6K are the 50% effective concentrations 
of ERK and S6K for proliferation, respectively. IC50ERK 
and IC50S6K are the 50% inhibitory concentrations of ERK 
and S6K for cell death, respectively. The parameters were 
obtained by minimizing the residual sum square (RSS):







where Proliferationex represents the normalized total cell 
number, which is the sum of the data of the MTT (live 
cells) and LDH (dead cells) assays (0 < Proliferationex 
< 1), and Deathex represents the number of dead 
cells, measured by the LDH assay. i indicates the i-th 
experimental conditions. By optimizing these parameters, 
the contributions of ERK and S6K to proliferation and cell 
death were obtained as a Hill function.
ACKNOWLEDGMENTS
We thank Coumaran Egile and Vincent Loic 
for insightful discussion regarding the data. We thank 
Merck KGaA and Sanofi for providing pimasertib and 
SAR245409, respectively. We thank Editage (www.
editage.com) for English language editing.
This work was financially supported by Grants-
in-Aid for Scientific Research (B) (26290053) and (C) 
(26462515) and Grants-in-Aid for Young Scientific 
Research (B) (25893229, 15K20128, and 25861471) from 
the Ministry of Education, Culture, Sports, Science, and 
Technology of Japan. This study was also performed as 
a research program of the Project for Development of 
Innovative Research on Cancer Therapeutics (P-Direct), 
Ministry of Education, Culture, Sports, Science, and 
Technology of Japan.
CONFLICTS OF INTEREST
The authors report no conflicts of interest.
REFERENCES
1. Sankaranarayanan R, Ferlay J. Worldwide burden of 
gynaecological cancer: the size of the problem. Best Pract 
Res Clin Obstet Gynaecol. 2006; 20:207-25.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence 
and mortality worldwide: sources, methods and major patterns 
in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-86.
3. Harrison ML, Jameson C, Gore ME. Mucinous ovarian 
cancer. Int J Gynecol Cancer. 2008; 18:209-14.
4. Davidson B, Tropé CG. Ovarian cancer: diagnostic, 
biological and prognostic aspects. Womens Health (Lond 
Engl). 2014; 10:519-33.
5. Hart WR. Mucinous tumors of the ovary: a review. Int J 
Gynecol Pathol. 2005; 24:4-25.
6. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton 
DP, Shepherd JH, Ind T, Bridges J, Harrington K, Kaye SB, 
Gore ME. Mucinous epithelial ovarian cancer: a separate 
entity requiring specific treatment. J Clin Oncol. 2004; 
22:1040-4.
7. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, 
Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot 
CV, Bottsford-Miller J, et al. Targeting SRC and tubulin 
in mucinous ovarian carcinoma. Clin Cancer Res. 2013; 
19:6532-43.
8. Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, 
Shimada M, Kigawa J, Harada T. Dual inhibition of 
phosphatidylinositol 3'-kinase and mammalian target of 
rapamycin using NVP-BEZ235 as a novel therapeutic 
approach for mucinous adenocarcinoma of the ovary. Int J 
Gynecol Cancer. 2014; 24:444-53.





9. Network CGAR. Integrated genomic analyses of ovarian 
carcinoma. Nature. 2011; 474:609-15.
10. Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, 
Rowley SM, Christie M, Allan PE, Stephens A, Bowtell 
DD, Campbell IG, Gorringe KL. Mutational landscape of 
mucinous ovarian carcinoma and its neoplastic precursors. 
Genome Med 2015; 7:87.
11. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, 
Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM. 
Frequent activating mutations of PIK3CA in ovarian clear 
cell carcinoma. Am J Pathol. 2009; 174:1597-601.
12. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, 
McCormick F. Cancer targets in the Ras pathway. Cold 
Spring Harb Symp Quant Biol. 2005; 70:461-7.
13. Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan 
J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, 
Kleinschmidt M, Kinross KM , et al. Synergistic inhibition 
of ovarian cancer cell growth by combining selective PI3K/
mTOR and RAS/ERK pathway inhibitors. Eur J Cancer. 
2013; 49:3936-44.
14. Barretina J, Caponigro G, Stransky N, Venkatesan K, 
Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, 
Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer 
Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature. 2012; 483:603-7.
15. Won JK, Yang HW, Shin SY, Lee JH, Heo WD, Cho KH. 
The crossregulation between ERK and PI3K signaling 
pathways determines the tumoricidal efficacy of MEK 
inhibitor. J Mol Cell Biol. 2012; 4:153-63.
16. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar 
R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards 
R. Unresponsiveness of colon cancer to BRAF(V600E) 
inhibition through feedback activation of EGFR. Nature. 
2012; 483:100-3.
17. Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama 
T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-
Hiraike O, Kawana K, Yano T, et al. Antitumor activity of 
a combination of dual PI3K/mTOR inhibitor SAR245409 
and selective MEK1/2 inhibitor pimasertib in endometrial 
carcinomas. Gynecol Oncol. 2015; 138:323-31.
18. Miyawaki A. Visualization of the spatial and temporal 
dynamics of intracellular signaling. Dev Cell. 2003; 
4:295-305.
19. Miyawaki A. Development of probes for cellular functions 
using fluorescent proteins and fluorescence resonance 
energy transfer. Annu Rev Biochem. 2011; 80:357-73.
20. Fujita Y, Komatsu N, Matsuda M, Aoki K. Fluorescence 
resonance energy transfer based quantitative analysis of 
feedforward and feedback loops in epidermal growth factor 
receptor signaling and the sensitivity to molecular targeting 
drugs. FEBS J. 2014; 281:3177-92.
21. Komatsu N, Fujita Y, Matsuda M, Aoki K. mTORC1 
upregulation via ERK-dependent gene expression change 
confers intrinsic resistance to MEK inhibitors in oncogenic 
KRas-mutant cancer cells. Oncogene. 2015; 34:5607-16.
22. Jares-Erijman EA, Jovin TM. FRET imaging. Nat 
Biotechnol. 2003; 21:1387-95.
23. Kamioka Y, Yasuda S, Fujita Y, Aoki K, Matsuda M. 
Multiple decisive phosphorylation sites for the negative 
feedback regulation of SOS1 via ERK. J Biol Chem. 2010; 
285:33540-8.
24. Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou 
XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, 
Morrison DK. Regulation of Raf-1 by direct feedback 
phosphorylation. Mol Cell. 2005; 17:215-24.
25. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt 
N, Braun S, Brummer T, Sers C, Blüthgen N. Strong 
negative feedback from Erk to Raf confers robustness to 
MAPK signalling. Mol Syst Biol. 2011; 7:489.
26. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs 
G, de Matos Simoes R, Carugo O, Baccarini M. A Mek1-
Mek2 heterodimer determines the strength and duration of 
the Erk signal. Nat Struct Mol Biol. 2009; 16:294-303.
27. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-
mTOR pathways: cross-talk and compensation. Trends 
Biochem Sci. 2011; 36:320-8.
28. Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung 
L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, 
Yilmaz ÖH, Bronson RT, Martin ES, Tsichlis PN, et al. 
Combination PI3K/MEK inhibition promotes tumor 
apoptosis and regression in PIK3CA wild-type, KRAS 
mutant colorectal cancer. Cancer Lett. 2014; 347:204-11.
29. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, 
Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, 
Chirieac LR, Kaur R, Lightbown A, et al. Effective use of 
PI3K and MEK inhibitors to treat mutant Kras G12D and 
PIK3CA H1047R murine lung cancers. Nat Med. 2008; 
14:1351-6.
30. Guenther MK, Graab U, Fulda S. Synthetic lethal 
interaction between PI3K/Akt/mTOR and Ras/MEK/ERK 
pathway inhibition in rhabdomyosarcoma. Cancer Lett. 
2013; 337:200-9.
31. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak 
D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations 
in the phosphatidylinositol-3-kinase pathway predict 
for antitumor activity of the inhibitor PX-866 whereas 
oncogenic Ras is a dominant predictor for resistance. 
Cancer Res. 2009; 69:143-50.
32. Britten CD. PI3K and MEK inhibitor combinations: 
examining the evidence in selected tumor types. Cancer 
Chemother Pharmacol. 2013; 71:1395-409.
33. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009; 
4:287-313.
34. Lee SY, Tyler JY, Kim S, Park K, Cheng JX. FRET 
imaging reveals different cellular entry routes of self-
assembled and disulfide bonded polymeric micelles. Mol 
Pharm. 2013; 10:3497-506.
35. Janssen A, Beerling E, Medema R, van Rheenen J. Intravital 
FRET imaging of tumor cell viability and mitosis during 
chemotherapy. PLoS One. 2013; 8:e64029.
Oncotarget29591www.impactjournals.com/oncotarget
36. Abe K, Zhao L, Periasamy A, Intes X, Barroso M. Non-
invasive in vivo imaging of near infrared-labeled transferrin 
in breast cancer cells and tumors using fluorescence lifetime 
FRET. PLoS One. 2013; 8:e80269.
37. Infante JR, Gandi L, Shapiro G, Rizvi N, Burris HA, 
Bendell JC, Baselga J, Hsu K, Richter O, Locatelli G, 
Asatiani E, Heist RS. Combination of the MEK inhibitor, 
pimasertib (MSC1936369B), and the PI3K/mTOR 
inhibitor, SAR245409, in patients with advanced solid 
tumors: Results of a phase Ib dose-escalation trial. Cancer 
Res 2013; 73:Abstract nr LB-147. doi:10.1158/1538-7445.
AM2013-LB-147.
38. Sidhu SS, Campana F, Egile C, Hsu K, Goodstal S, Asatiani 
E, Damstrup L, Lager J, Ogden J, Vincent L. Anti-tumor 
activity of the MEK inhibitor pimasertib in combination 
with the PI3K/mTOR inhibitor SAR245409 in low-grade 
serous ovarian cancer. Clin Cancer Res 2013; 19:Abstract 
nr A48. doi: 10.1158/1078-0432.OVCA13-A48.
39. Yu P, Laird AD, Du X, Wu J, Won KA, Yamaguchi K, 
Hsu PP, Qian F, Jaeger CT, Zhang W, Buhr CA, Shen P, 
Abulafia W, et al. Characterization of the activity of the 
PI3K/mTOR inhibitor XL765 (SAR245409) in tumor 
models with diverse genetic alterations affecting the PI3K 
pathway. Mol Cancer Ther. 2014; 13:1078-91.
40. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, 
Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, 
Munshi NC, Richardson P, et al. Blockade of the MEK/ERK 
signalling cascade by AS703026, a novel selective MEK1/2 
inhibitor, induces pleiotropic anti-myeloma activity in vitro 
and in vivo. Br J Haematol. 2010; 149:537-49.
41. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone 
K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, 
Koso T, Matsumoto Y, Wada-Hiraike O, et al. Genotype-
dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-
BEZ235, and an mTOR inhibitor, RAD001, in endometrial 
carcinomas. PLoS One. 2012; 7:e37431.
42. Barretina J, Caponigro G, Stransky N, Venkatesan K, 
Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, 
Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer 
Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature. 2012; 483:603-7.
43. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, 
Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, 
Shokat KM, McCormick F. PIK3CA cooperates with other 
phosphatidylinositol 3'-kinase pathway mutations to effect 
oncogenic transformation. Cancer Res. 2008; 68:8127-36.
44. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to 
ImageJ: 25 years of image analysis. Nat Methods. 2012; 
9:671-5.
45. Chou TC. Drug combination studies and their synergy 
quantification using the Chou-Talalay method. Cancer Res. 
2010; 70:440-6.
46. Komatsu N, Aoki K, Yamada M, Yukinaga H, Fujita Y, 
Kamioka Y, Kamioka Y, Matsuda M. Development of an 
optimized backbone of FRET biosensors for kinases and 
GTPases. Mol Biol Cell. 2011; 22:4647-56.
47. Aoki K, Komatsu N, Hirata E, Kamioka Y, Matsuda M. 
Stable expression of FRET biosensors: a new light in cancer 
research. Cancer Sci. 2012; 103:614-9.
48. Aoki K, Matsuda M. Visualization of small GTPase 
activity with fluorescence resonance energy transfer-based 
biosensors. Nat Protoc. 2009; 4:1623-31.
